BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24470149)

  • 1. Successful allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning for B-cell prolymphocytic leukemia in partial remission.
    Arima H; Ono Y; Tabata S; Matsushita A; Hashimoto H; Ishikawa T; Takahashi T
    Int J Hematol; 2014 Apr; 99(4):519-22. PubMed ID: 24470149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential Kinase Inhibition (Idelalisib/Ibrutinib) Induces Clinical Remission in B-Cell Prolymphocytic Leukemia Harboring a 17p Deletion.
    Coelho H; Badior M; Melo T
    Case Rep Hematol; 2017; 2017():8563218. PubMed ID: 28819574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of Late Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with T-Cell Prolymphocytic Leukemia.
    Shumilov E; Hasenkamp J; Szuszies CJ; Koch R; Wulf GG
    Acta Haematol; 2021; 144(1):105-110. PubMed ID: 32259827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allogeneic bone marrow transplantation in a patient with T-prolymphocytic leukemia with small-intestinal involvement.
    Murase K; Matsunaga T; Sato T; Kuribayashi K; Kogawa K; Kawano Y; Okamoto T; Takayama T; Watanabe H; Niitsu Y; Hirayama Y
    Int J Clin Oncol; 2003 Dec; 8(6):391-4. PubMed ID: 14663643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic hematopoietic stem cell transplantation for T-prolymphocytic leukemia: a report from the French society for stem cell transplantation (SFGM-TC).
    Guillaume T; Beguin Y; Tabrizi R; Nguyen S; Blaise D; Deconinck E; Redjoul R; Cornillon J; Guillerm G; Contentin N; Sirvent A; Turlure P; Salmon A; Huynh A; François S; Peffault de Latour R; Yakoub-Agha I; Mohty M
    Eur J Haematol; 2015 Mar; 94(3):265-9. PubMed ID: 25130897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience.
    Dholaria BR; Ayala E; Sokol L; Nishihori T; Chavez JC; Hussaini M; Kumar A; Kharfan-Dabaja MA
    Leuk Res; 2018 Apr; 67():1-5. PubMed ID: 29407180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature.
    Zhang C; Kong PY; Li S; Chen T; Ni X; Li Y; Wang M; Liu Y; Gao L; Gao L; Peng XG; Sun AH; Wang P; Yang Z; Zhang X; Qian C
    J Immunother; 2018; 41(6):306-311. PubMed ID: 29864079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B- and T-cell prolymphocytic leukemia: antibody approaches.
    Dearden C
    Hematology Am Soc Hematol Educ Program; 2012; 2012():645-51. PubMed ID: 23233647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.
    Hwang YY; Mohty M; Chim CS
    Hematology; 2015 Mar; 20(2):61-71. PubMed ID: 24993587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Progress of research on allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning regimen for treatment of myelodysplastic syndrome - review].
    Zhang Z; Li X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):969-74. PubMed ID: 18718102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium.
    Wiktor-Jedrzejczak W; Dearden C; de Wreede L; van Biezen A; Brinch L; Leblond V; Brune M; Volin L; Kazmi M; Nagler A; Schetelig J; de Witte T; Dreger P;
    Leukemia; 2012 May; 26(5):972-6. PubMed ID: 22116553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic hematopoietic stem cell transplantation for acute leukemia patients: a single center experience.
    Goker H; Ozdemir E; Uz B; Buyukasik Y; Turgut M; Serefhanoglu S; Aksu S; Sayinalp N; Haznedaroglu IC; Tekin F; Karacan Y; Unal S; Eliacik E; Isik A; Ozcebe OI
    Transfus Apher Sci; 2013 Dec; 49(3):590-9. PubMed ID: 23981652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Feasibility of Allogeneic Hematopoietic Stem-Cell Transplantation in the Treatment of Refractory Acute Myeloid Leukemia.
    Ciftciler R; Demiroglu H; Buyukasık Y; Aladag E; Aksu S; Haznedaroglu IC; Sayınalp N; Ozcebe O; Malkan UY; Goker H
    Clin Lymphoma Myeloma Leuk; 2019 Mar; 19(3):177-182. PubMed ID: 30616990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tandem Allogeneic Hematopoietic Stem Cell Transplantation for Salvage Treatment of Acute Myeloid Leukemia Refractory to Induction Chemotherapy: A Case Report.
    Drozd-Sokolowska J; Dwilewicz-Trojaczek J; Tormanowska M; Karakulska-Prystupiuk E; Sachs W; Halaburda K; Urbanowska E; Gierej B; Basak GW; Wiktor-Jedrzejczak W
    Transplant Proc; 2020 Oct; 52(8):2548-2550. PubMed ID: 32571713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of post-remission chemotherapy before allo-HSCT for acute myeloid leukemia during first complete remission: a meta-analysis.
    Zhu Y; Gao Q; Du J; Hu J; Liu X; Zhang F
    Ann Hematol; 2018 Sep; 97(9):1519-1526. PubMed ID: 29946906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central Nervous System Involvement at the Time of Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with a Poor Outcome in Patients with Acute Myeloid Leukemia.
    Ikegawa S; Doki N; Kaito S; Kurosawa S; Sakaguchi M; Harada K; Yamamoto K; Hino Y; Shingai N; Senoo Y; Watanabe D; Hagino T; Yoshioka K; Watakabe K; Igarashi A; Najima Y; Kobayashi T; Kakihana K; Sakamaki H; Ohashi K
    Pathol Oncol Res; 2017 Apr; 23(2):433-437. PubMed ID: 28004352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of myeloablative allogeneic hematopoietic stem cell transplantation in adult patients with MLL-ELL-positive acute myeloid leukemia.
    Muto T; Takeuchi M; Yamazaki A; Sugita Y; Tsukamoto S; Sakai S; Takeda Y; Mimura N; Ohwada C; Sakaida E; Aotsuka N; Iseki T; Nakaseko C
    Int J Hematol; 2015 Jul; 102(1):86-92. PubMed ID: 25758097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Comparison of autologous and allogeneic hematopoietic stem cell transplantation for 140 patients with de novo acute leukemia in first complete remission].
    Wang HH; Feng SZ; Wang M; Wei JL; Jiang EL; Zhang L; Huang Y; Zhou SY; Liu QG; Qiu LG; Han MZ; Yan WW
    Zhonghua Xue Ye Xue Za Zhi; 2004 Jul; 25(7):389-92. PubMed ID: 15355688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome and Minimal Residual Disease Monitoring in Patients with t(16;21) Acute Myelogenous Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
    Qin YZ; Chen Y; Xu LP; Wang Y; Zhang XH; Chen H; Zhao XS; Liu KY; Huang XJ
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):163-168. PubMed ID: 28939454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.